GC Email
Feb. 16, 2017
Biosimilar battle heads to high court
The Supreme Court's interpretation of key provisions of the Biologics Price Competition and Innovation Act will have a significant impact on how long it takes to bring biosimilars to market. By Shawn G. Hansen
Shawn G. Hansen
Nixon Peabody LLPintellectual property litigation
300 S Grand Ave Ste 4100
Los Angeles , CA 90071-3151
Phone: (213) 629-6190
Fax: (855) 780-9262
Email: shansen@nixonpeabody.com
UC Hastings
Shawn G. Hansen is an IP Litigation partner at Nixon Peabody LLP with offices in Los Angeles and San Francisco
In the U.S. Supreme Court's first term during the new administration, the court will take up one of the least known but most important parts of the Affordable Care Act (ACA) in Amgen v. Sandoz. This case will interpret key provisions of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) that was enacted as part of the ACA to help reduce health care costs by creating an expedited path to market for "biosi...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In